# Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)

> **NCT00839436** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 21 (actual)

## Conditions studied

- Idiopathic CD4+ T-Lymphocytopenia

## Interventions

- **DRUG:** CYT107

## Key facts

- **NCT ID:** NCT00839436
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2014-05
- **Final completion:** 2014-09
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Bankruptcy of Drug manufacturer: Drug not available
- **Last updated:** 2015-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00839436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00839436, "Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00839436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*